重新评估大前庭导水管
这项单中心纵向回顾性队列研究分析了2003年3月至2022年10月在中国人民解放军总医院就诊的2774例大前庭导水管(EVA)患者,中位年龄8岁,95.9%携带双等位基因SLC26A4变异。研究描述自然史、表型与基因型谱,强调定期听力监测和个体化遗传咨询的重要性。
要点
- 2774例EVA患者中95.9%携带双等位基因SLC26A4变异,2.5%为拷贝数变异,0.5%为深内含子变异。
- 341例接受新生儿听力筛查的患者中124例(36.36%)通过,597例中375例(62.8%)经听力与影像联合诊断。
- 597例中反复眩晕256例(42.9%)、甲状腺肿38例(6.4%);作者强调定期听力监测与个体化遗传咨询。
核心结论
- 作者认为定期听力监测和个体化遗传咨询对EVA患者重要,对预防、管理及未来基因治疗有重要意义。
- 本研究提供EVA广泛的表型和基因型特征,可能促进对其分子基础和临床异质性的理解。
研究设计与样本
- 单中心、纵向、回顾性队列研究,2003年3月至2022年10月开展,随访至2024年7月1日。
- 纳入在中国人民解放军总医院就诊的EVA患者,共2774例,女性1453例(52.4%),中位年龄8岁(范围4个月至45岁)。
主要发现
- 341例接受新生儿听力筛查的EVA患者中124例(36.36%)通过筛查。
- 597例中375例(62.8%)通过听力与影像联合评估获得诊断。
- 597例中反复眩晕256例(42.9%),甲状腺肿38例(6.4%)。
- 2774例中2661例(95.9%)携带双等位基因SLC26A4变异,其中70例(2.5%)归因于拷贝数变异,13例(0.5%)归因于影响剪接的深内含子变异(c.304 + 941C>T)。
- 在一个EVA家系中鉴定出新生杂合FOXI1变异(c.483_485delCAA),提示常染色体显性遗传模式。
关键数值与推荐
- 阶梯式基因组分析策略与95.9%的分子诊断率提高相关,凸显传统编码区之外全面基因检测的必要性。
临床怎么用
- 作者认为对EVA患者应进行定期听力监测和个体化遗传咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Enlarged vestibular aqueduct (EVA), the most prevalent inner ear malformation causing hearing loss (HL) in various populations, is predominantly genetically mediated. Despite advancements in genetic diagnostics, the comprehensive phenotypic and genotypic spectrum of EVA remains insufficiently characterized. OBJECTIVES: To characterize the natural history, clinical outcomes, phenotype, and genotype of EVA. DESIGN, SETTING, AND PARTICIPANTS: This single-center, longitudinal, retrospective cohort study was conducted from March 2003 to October 2022, with follow-up until July 1, 2024. Patients with EVA who were seeking medical advice at the Chinese PLA General Hospital were included. MAIN OUTCOMES AND MEASURES: This study presents a 21-year longitudinal analysis of Chinese patients with EVA, providing a systematic analysis of the natural history, phenotypic diversity, and molecular etiology of EVA. RESULTS: Of 2774 patients, 1453 (52.4%) were female individuals, and the median (range) age was 8 (4 months to 45 years) years. This study identified that 124 of 341 patients (36.36%) with EVA received passing newborn hearing screening results, while 375 of 597 (62.8%) received a diagnosis through combined audiological and radiological assessments. Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common comorbidities. Genetic analysis revealed that 2661 of 2774 patients (95.9%) carried biallelic SLC26A4 variants, with 70 (2.5%) attributable to copy number variants and 13 (0.5%) to a deep-intronic variant (c.304 + 941C>T) that affected splicing. A de novo heterozygous FOXI1 variant (c.483_485delCAA) was identified in an EVA family, indicating an autosomal dominant inheritance pattern. A stepped genomic analysis strategy was associated with an improved molecular diagnosis rate of 95.9%, highlighting the necessity of comprehensive genetic testing beyond traditional coding regions. CONCLUSIONS AND RELEVANCE: The results of this cohort study underscore the importance of periodic hearing surveillance and tailored genetic counseling for patients with EVA, offering substantial implications for prevention, management, and future gene therapy approaches. This study provides an extensive phenotypic and genotypic characterization of EVA, potentially advancing an understanding of its molecular underpinnings and clinical heterogeneity.
引用
- Huang S, Gao X, Jiang Y, et al. Reevaluation of Enlarged Vestibular Aqueduct. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 41066100. doi:10.1001/jamaoto.2025.2866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。